BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:HM15275 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of HM15275\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07205900-232@assetmemo.bio
DTSTAMP:20261121T004101Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:HM15275: Phase 2 readout est. (NCT07205900)
DESCRIPTION:HM15275\, phase 2\, Obesity.\nStudy: Study to Evaluate HM15275 
 in Obese or Overweight Subjects Without Diabetes Mellitus\nEstimated prima
 ry completion: January 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/hm15275#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07205900
URL:https://assetmemo.bio/drug/hm15275#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07527650-232@assetmemo.bio
DTSTAMP:20261121T004101Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:HM15275: Phase 2 readout est. (NCT07527650)
DESCRIPTION:HM15275\, phase 2\, Type 2 Diabetes.\nStudy: Study to Evaluate 
 HM15275 in Subjects With Type 2 Diabetes Mellitus\nEstimated primary compl
 etion: October 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 hm15275#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07527650
URL:https://assetmemo.bio/drug/hm15275#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
